Keep it Simple: A Compelling Indication for GLP-1 RAs in Diabetes
August 28, 2020
August 28, 2021
Scroll to the Bottom of this Information to Begin this Course
Sponsored by The Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
- Physicians — maximum of 0.25 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
This activity is intended for primary care physicians and other healthcare practitioners treating patients with diabetes, including endocrinologists, to provide practical guidance to help clinicians reduce the risk of MACE in patients with Type 2 Diabetes.
In this activity, Dr. John B. Buse and Dr. Christian T. Ruff present a patient case and share their personal approach to reducing the risk of cardiovascular disease in diabetic patients. They review the efficacy and safety of GLP-1 RA and cardiovascular outcomes trials as they walk through cardiovascular risk stratification and treatment selection for a patient with atherosclerotic cardiovascular disease.
Cardiovascular mortality remains the leading cause of death in patients with Type 2 Diabetes (T2D), and clinicians must be knowledgeable on the therapeutic agents that offer cardioprotective benefits, such as GLP-1 receptor agonists (GLP-1 RAs). In this activity, expert faculty provide practical strategies to help clinicians assess the risk of major adverse cardiovascular events (MACE) in patients with T2D and inform therapeutic selection considerate of the individual patient.
Upon completion of this activity, participants should be better able to:
- Describe a comprehensive treatment plan—considerate of patient preferences and individualized glycemic goals—for T2D patients at elevated risk for CVD and those already diagnosed with ASCVD
- Review CVOT and real-world evidence regarding primary and secondary prevention of CVD
- Outline cardiovascular risk stratification strategies to effectively screen patients with T2D
John B. Buse, MD, PhD
Chief, Division of Endocrinology
Director, Diabetes Center
University of North Carolina School of Medicine
Chapel Hill, NC
Christian T. Ruff, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Brigham and Women’s Hospital
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:
John B. Buse, MD, PhD
- Consultant: Cirius Therapeutics Inc, CSL Behring, Mellitus Health, Neurimmune AG, Pendulum Therapeutics, Stability Health
- Research Support: NovaTarg Therapeutics, Novo Nordisk, Sanofi, Tolerion, vTv Therapeutics
Christian T. Ruff, MD, MPH
- Consultant: Bayer, Boehringer Ingelheim, Daiichi Sankyo, Portola
- Research Support: Daiichi Sankyo
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Instructions for Participation and Credit
This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions about this activity, please contact Laurie Novoryta at Lnovoryta@achlcme.org.
Course Viewing Requirements
- Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
- Compatible with Windows PC and MAC (256 MB of RAM or higher)
- Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
- Adobe Flash Player 12.0 (or higher).
- Adobe Reader to print certificate.
- Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Disclosure of Unlabeled Use
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.